ReviewTherapeutic advances in endocrinology and metabolism2024
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor.
Review in Therapeutic advances in endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Effects ofMolecules (Basel, Switzerland) · 2026Article
- Association Between Depressive Symptoms and Incidence of Stroke in a Population With Cardiovascular-Kidney-Metabolic Syndrome Stages 0 to 3: Nationwide Prospective Cohort Study.Interactive journal of medical research · 2026Article
- Selected Parameters Which Support the Laboratory Diagnosis of Cardiovascular-Kidney-Metabolic Syndrome in the Light of Current Guidelines: A Narrative Review.Journal of clinical medicine · 2026Review
- The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.Acta biochimica Polonica · 2026Review
- Low physical activity-related disease burden, 1990-2021: assessment of global trends and social determinants based on GBD 2021 data.Journal of global health · 2025Article
- Inflammatory markers predict MIA syndrome progression and cardiovascular disease outcomes in maintenance dialysis patients.BMC nephrology · 2025Article
- Measurement of serum adropin levels in chronic renal failure patients receiving routine hemodialysis treatment.Medicine · 2025Observational
- Prevalence of metabolic syndrome in people living with HIV and its multi-organ damage: a prospective cohort study.BMC infectious diseases · 2025Article
- Prognostic nutritional index predicts staging and mortality in cardiovascular-kidney-metabolic syndrome.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a group of conditions characterized by hypertension (HTN), hyperglycaemia or insulin resistance (IR), hyperlipidaemia, and abdominal obesity. MetS is associated with a high incidence of cardiovascular events and mortality and is an independent risk factor for chronic kidney disease (CKD). MetS can cause CKD or accelerate the progression of kidney disease. Recent studies have found that MetS and kidney disease have a cause-and-effect relationship. Patients with CKD, those undergoing kidney transplantation, or kidney donors have a significantly higher risk of developing MetS than normal people. The present study reviewed the possible mechanisms of MetS in patients with CKD, including the disorders of glucose and fat metabolism after kidney injury, IR, HTN and the administration of glucocorticoid and calcineurin inhibitors. In addition, this study reviewed the effect of MetS in patients with CKD on important target organs such as the kidney, heart, brain and blood vessels, and the treatment and prevention of CKD combined with MetS. The study aims to provide strategies for the diagnosis, treatment and prevention of CKD in patients with MetS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.